Eddie Cliff, Haematology Registrar at Peter MacCallum Cancer Centre, shared on X:
“Informative molecular analyses from TRIANGLE trial in mantle cell lymphoma, showing that the benefit for ibrutinib arms is driven by the TP53mut cohort.
Promising outcomes for TP53mut disease treated with TRIANGLE (2yr PFS ~75%)
Comparable to BOVen?”
Other articles about Mantle Cell Lymphoma on OncoDaily.
